UPDATE - Canaccord Genuity Downgraded Protalix BioTherapeutics (PLX) to Hold; Taking A Good Look

May 2, 2012 10:14 AM EDT
Get Alerts PLX Hot Sheet
Price: $2.38 --0%

Rating Summary:
    3 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - Canaccord Genuity downgraded Protalix BioTherapeutics (NYSE: PLX) from Buy to Hold, maintains price target of $8.00.

Analyst, Ritu Baral, said, "We see modest US but robust Israel/ROW potential with approval, EU may be blocked by Vpriv orphan – waiting for Fabry program to drive catalysts. We think PLX/partner Pfizer’s (NYSE: PFE) Elelyso (taliglucerase) may get ~15% of the $1.2B+ worldwide Gaucher’s market. Our target is now based on a DCF of projected US/IROW sales and pNPV of forecasted EU sales. Our target is unchanged; removal of FDA risk offsets lower EU pNPV."

To see more ratings on PLX, Click Here


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades